Evidence map›Paper›PMID 26268325›Full record

ArticleBMC biotechnology2015

Cytokine detection and simultaneous assessment of rheumatoid factor interference in human serum and synovial fluid using high-sensitivity protein arrays on plasmonic gold chips.

Manfè Valentina, Fleckner Jan, Nørby Lisby Peder, Zhang Bo, Dai Hongjie, Keller Pernille

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Cytokines: From Clinical Significance to Quantification.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Manfè ValentinaDepartment of PharmacoGenetics, Biopharmaceutical Research Unit, Novo Nordisk A/S, Novo Nordisk Park 1, Maaloev, 2760, Denmark. vlmn@novonordisk.com.
Fleckner JanDepartment of PharmacoGenetics, Biopharmaceutical Research Unit, Novo Nordisk A/S, Novo Nordisk Park 1, Maaloev, 2760, Denmark.
Nørby Lisby PederDepartment of PharmacoGenetics, Biopharmaceutical Research Unit, Novo Nordisk A/S, Novo Nordisk Park 1, Maaloev, 2760, Denmark.
Zhang BoDepartment of Chemistry, Stanford University, San Francisco, CA, USA.
Dai HongjieDepartment of Chemistry, Stanford University, San Francisco, CA, USA.
Keller PernilleDepartment of PharmacoGenetics, Biopharmaceutical Research Unit, Novo Nordisk A/S, Novo Nordisk Park 1, Maaloev, 2760, Denmark.
Novo Nordisk (Denmark) · DKStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFluorescence-enhancing microarray on plasmonic gold film is an attractive alternative to traditional enzyme-linked immunosorbent assay (ELISA) for cytokine detection because of the increased sensitivity. The assay chemistry is similar to an ELISA sandwich assay, but owing to the gold substrate, cytokine measurements are 10 to 100 times more sensitive and can be multiplexed. Plasmonic protein microarrays are, as other immunoassays, affected by the presence of heterophilic antibodies and rheumatoid factor may lead to analytical errors with serious implications for patient care. Here, we present a plasmonic gold substrate protein microarray for high-sensitivity detection of cytokines with simultaneous assessment of rheumatoid factor interference on a single chip.

resultsPaired serum and synovial fluid samples from patients with rheumatoid arthritis (n = 18), osteoarthritis (n = 9) or healthy controls (n = 10) were arrayed on near-infrared fluorescence enhancing plasmonic gold chips spotted with cytokine-specific capture antibody and isotype control antibody. Possible rheumatoid factor interference was visualised by a non-specific signal from the isotype control antibody, and pre-treatment of samples with heat-aggregated animal IgG eliminated this background contamination. The platform was optimised using the cytokine IL-20. The protein microarray platform allowed for the detection of human IL-20 at levels <1 pg/ml with reliable IL-20 quantification over a 5-log dynamic range. Samples for which rheumatoid factor caused artefacts were identified and a method for eliminating rheumatoid factor interference was developed and validated. IL-20 protein levels were significantly higher in synovial fluid samples from patients with rheumatoid arthritis compared to osteoarthritis (p < 0.001), while serum levels of IL-20 did not differ between patients with rheumatoid arthritis, osteoarthritis or healthy controls.

conclusionUsing novel plasmonic gold chips, we developed a highly sensitive and accurate assay platform to detect lowly expressed cytokines in biological fluids, allowing for the elimination of rheumatoid factor interference in as little as 5 μl sample volume. The detection limit was below 1 pg/ml for IL-20 and linearity was achieved over a 5-log dynamic range. This technology is highly advantageous for cytokines where sensitivity or sample volume is critical or where assessment of rheumatoid factor interference needs addressed and eliminated.

Indexed as

AnimalsArthritis, RheumatoidFemaleGoldHumansImmunoassayInterleukinsMaleOsteoarthritisProtein Array AnalysisRheumatoid FactorSynovial FluidGoldinterleukin 20InterleukinsRheumatoid Factor

Identifiers

PMID26268325
PMCPMC4535377
OpenAlexW1882182585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.